These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 20524436)

  • 1. A study of cycle control, side effects and client's satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone (24/4 regimen).
    Chaiyasit N; Taneepanichskul S
    J Med Assoc Thai; 2010 May; 93(5):517-22. PubMed ID: 20524436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.
    Bachmann G; Sulak PJ; Sampson-Landers C; Benda N; Marr J
    Contraception; 2004 Sep; 70(3):191-8. PubMed ID: 15325887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cycle control, safety and acceptability of a new oral contraceptive containing ethinylestradiol 15 micrograms and gestodene 60 micrograms.
    Jaithitivit L; Jaisamrarn U; Taneepanichskul S
    J Med Assoc Thai; 2012 May; 95(5):630-5. PubMed ID: 22994020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.
    Jensen JT; Garie SG; Trummer D; Elliesen J
    Contraception; 2012 Aug; 86(2):110-8. PubMed ID: 22281416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective follow-up of two 21/7 cycles followed by two extended regimen 84/7 cycles with contraceptive pills containing ethinyl estradiol and drospirenone.
    Seidman DS; Yeshaya A; Ber A; Amodai I; Feinstein I; Finkel I; Gordon N; Porat N; Samuel D; Shiran-Makler E; Wolman I
    Isr Med Assoc J; 2010 Jul; 12(7):400-5. PubMed ID: 20862819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
    Borges LE; Andrade RP; Aldrighi JM; Guazelli C; Yazlle ME; Isaia CF; Petracco A; Peixoto FC; Camargos AF
    Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in a 24+4-day regimen in China].
    Caiyan W; Wen D; Qinping L; Huan S; Ziyan H; Liangdan T; Zheng'ai X; Yufeng L; Shulan Z; Baihua D; Xiaoyan X; Mulan R; Xiaomao L; Youdi X; Zhisong M; Meiqing X; Hongyu W; Zirong H
    Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):355-9. PubMed ID: 25030732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
    Marr J; Gerlinger C; Kunz M
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen.
    Hernádi L; Marr J; Trummer D; De Leo V; Petraglia F
    Contraception; 2009 Jul; 80(1):18-24. PubMed ID: 19501211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined hormonal contraception in cycles artificially extended].
    Bustillos-Alamilla E; Zepeda-Zaragoza J; Hernández-Ruiz MA; Briones-Landa CH
    Ginecol Obstet Mex; 2010 Jan; 78(1):37-45. PubMed ID: 20931801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
    Vree ML; Schmidt J
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
    Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
    Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone.
    Blode H; Klipping C; Richard F; Trummer D; Rohde B; Diefenbach K
    Contraception; 2012 Feb; 85(2):177-84. PubMed ID: 22067789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
    Anttila L; Kunz M; Marr J
    Contraception; 2009 Nov; 80(5):445-51. PubMed ID: 19835718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical study of a monophasic pill containing 20 microg ethinylestradiol and 150 microg desogestrel in Thai women.
    Jaisamrarn U; Reinprayoon D; Virutamasen P
    J Med Assoc Thai; 2001 Jun; 84 Suppl 1():S377-83. PubMed ID: 11529361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen.
    Brucker C; Hedon B; The HS; Höschen K; Binder N; Christoph A
    Contraception; 2010 Jun; 81(6):501-9. PubMed ID: 20472117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YAZ and the novel progestin drospirenone.
    Mishell DR
    J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.
    Apter D; Borsos A; Baumgärtner W; Melis GB; Vexiau-Robert D; Colligs-Hakert A; Palmer M; Kelly S
    Eur J Contracept Reprod Health Care; 2003 Mar; 8(1):37-51. PubMed ID: 12725674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contraceptive efficacy of a combined oral contraceptive containing ethinyloestradiol 20 μg/drospirenone 3mg administered in a 24/4 regimen: a pooled analysis of four open-label studies.
    Anttila L; Bachmann G; Hernádi L; Kunz M; Marr J; Klipping C
    Eur J Obstet Gynecol Reprod Biol; 2011 Apr; 155(2):180-2. PubMed ID: 21277674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.